跳至主要内容
临床试验/NCT04436822
NCT04436822已完成不适用

Evaluation of Updated Continuous Glucose Monitoring (CGM) Form Factor in Adults, Adolescents and Pediatrics

Medtronic Diabetes31 个研究点 分布在 2 个国家目标入组 317 人开始时间: 2020年7月15日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
317
试验地点
31
主要终点
Percentage of Readings Within 20% Agreement

研究概览

简要总结

The purpose of this study is to demonstrate the performance of the Disposable Sensor (DS5) in subjects age 2 - 80 years, for the span of 170 hours (7 days).

详细描述

The purpose of this study is to demonstrate the performance of the Disposable Sensor (DS5) in subjects age 2 - 80 years, for the span of 170 hours (7 days).

This is a multi-center study.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
2 Years 至 80 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Individual is 2 - 80 years of age at time of enrollment.
  • Subject has a clinical diagnosis of type 1 or type 2 diabetes:
  • If subject is 14-80 years of age, subject has a clinical diagnosis of type 1 or type 2 diabetes for a minimum of 6 months duration as determined via medical record/ source documentation by an individual qualified to make a medical diagnosis.
  • If subject is 2-13 years of age, subject has a clinical diagnosis of type 1 or type 2 diabetes as determined via medical record/ source documentation by an individual qualified to make a medical diagnosis.
  • If subject is participating in YSI™* FST , subject has adequate venous access as assessed by investigator or appropriate staff.
  • Subjects participating in the high and low glucose challenges must have an insulin carbohydrate ratio(s) and insulin sensitivity factor(s). Subjects without ratios may participate under observation only.

排除标准

  • Subject will not tolerate tape adhesive in the area of sensor placement as assessed by a qualified individual.
  • Subject has any unresolved adverse skin condition in the area of sensor or device placement (e.g., psoriasis, rash, Staphylococcus infection).
  • Subject is actively participating in an investigational study (e.g., drug or device) wherein he/she has received treatment from an investigational study (drug or device) in the last 2 weeks prior to Visit
  • (Please note participation in an observational study is acceptable.)
  • Subject is female of child-bearing potential and has a pregnancy screening test that is positive.
  • Subject is a sexually active female of child-bearing potential and is not using a form of contraception deemed reliable by investigator.
  • Subject is female and plans to become pregnant during the course of the study.
  • Subject has had a hypoglycemic seizure within the past 6 months prior to enrollment.
  • Subject has had hypoglycemia resulting in loss of consciousness within the past 6 months prior to enrollment.
  • Subject has had an episode of diabetic ketoacidosis (DKA) within the past 6 months prior to enrollment.
  • Subject has a history of a seizure disorder.
  • Subject has central nervous system or cardiac disorder resulting in syncope.
  • Subject has a history of myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack (TIA), cerebrovascular accident (CVA), angina, congestive heart failure, ventricular rhythm disturbances or thromboembolic disease
  • If subject is 7-80 years of age, subject has a hematocrit (Hct) more than 10% below the lower limit of normal reference range (please note that patients may use prior blood draw from routine care as long as done within 6 months of screening and report of lab placed with subject source documents).
  • Subject has a history of adrenal insufficiency.
  • Subject is a member of the research staff involved with the study.

结局指标

主要结局

Percentage of Readings Within 20% Agreement

时间窗: 7 days (170 hours)

Mean of daily percentage of sensor values within 20% of Yellow Springs Instrument (YSI™\*) reference value (within 20 mg/dL \[1.1 mmol/L\] when sensor values \< 80 mg/dL) \[4.4 mmol/L\]) by age groups and DS5 insertion locations. Note Self-Monitoring Blood Glucose (SMBG) was used for age 2-6, instead of YSI. Zero calibration sensor algorithm applied to raw sensor data.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (31)

Loading locations...

相似试验